The BIA together with the Wellcome Sanger Institute and the Medicines Discovery Catapult has launched a new report Genomics Nation, showcasing the strength, breadth and opportunity in the UK’s genomics sector.
The UK’s strength in genomics became evident during the pandemic, where we led the world in the early detection and monitoring of variants of SARS-CoV-2 thanks to a strong genomic infrastructure, a highly skilled workforce and an exceptional collaborative spirit. However, the applications of genomics extend far beyond COVID-19 and are leading the way for a healthier and more sustainable world
The BioIndustry Association (BIA), the Wellcome Sanger Institute and Medicines Discovery Catapult (MDC) have today launched Genomics Nation, showcasing the strength, breadth and opportunity of the UK’s genomics sector for investors, patients and the UK economy.
Biotech start-ups need substantial sums of money to fund their research and development activities. To attract investors and scale up their operations, founders must put some fundamental building blocks in place and avoid some common pitfalls.
• Follow-on investment, led by Epidarex Capital, closes at £4.24m, following initial £3.2m Seed round in 2020; Caribou Property joins as new investor
• Management appointments expand leadership team: Dr Steve Myatt, ex Azeria Therapeutics, to Chief Executive Officer; Dr Carola Ries, ex Roche, to Chief Scientific Officer; Co-founder Dr Luca Cassetta to move from his academic role at Edinburgh University to join as full-time VP Immunology
• Funds will accelerate macrophage-based therapeutics R&D portfolio and target discovery capability; expansion of facilities in Edinburgh and Cambridge
An ongoing strategic growth plan from Cytiva and Pall Corporation, part of the Danaher (NYSE: DHR) Corporation, will expand manufacturing capacity and services across geographies for global life sciences customers. The investment, already underway, includes new sites, expansion at existing factories, and is additional to previously announced investments. It follows five acquisitions made by the companies so far this year.
Cytena Bioprocess Solutions have recently launched their next generation microbioreactor, the S.NEST. This exceptional instrument features a patented mixing technology which creates an optimal suspension culture environment, as well as real-time monitoring of pH and dissolved oxygen, four individually controlled incubation chambers and sophisticated analytical software.
An innovative gene therapy programme which could pave the way for novel treatments for neurodegenerative diseases, has been launched at the University of Sheffield in collaboration with the Cell and Gene Therapy Catapult.
CPI Enterprises, the investor engagement and ventures arm of CPI, has made its first investment in Qualus, a cleantech firm working to reduce water and chemical consumption within the leather industry.